TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37053429
Drug: Electroconvulsive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroconvulsive therapy
Study: 33278614
Drug: Modular hemiarthroplasty
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modular hemiarthroplasty implant
Study: 33278614
Drug: Traditional monoblock
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional monoblock implant
Study: 33009228
Drug: PRC‐063 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRC‐063 (100 mg/d)
Study: 33009228
Drug: Immediate‐release methylphenidate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate‐release methylphenidate (20 mg, 3 times daily)
Study: 38048133
Drug: Calcium channel
Normalized name: Calcium channel blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium channel blocker (CCB)
Study: 35331230
Drug: Yoga with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yoga with high dose vitamin D (4000 IU)
Study: 35331230
Drug: Yoga with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yoga with low dose vitamin D (2000 IU)
Study: 35331230
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose vitamin D (4000 IU)
Study: 33222470
Drug: Sufentanil 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil 0.4 µg/kg
Study: 33222470
Drug: Fentanyl 4
Normalized name: fentanyl 400 MCG Buccal Film
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 4 µg/kg
Study: 33021585
Drug: Vitamins C
Normalized name: MULTIVITAMINS CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamins C (1 g) and E (800 UI) supplementation 40 minutes before exercise
Study: 34100742
Drug: Language intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Language intervention protocol combined with auditory verbal therapy (AVT)
Study: 34100742
Drug: Auditory verbal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auditory verbal therapy (AVT)
Study: 38154770
Drug: Clomiphene +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomiphene + Metformin
Study: 35779532
Drug: Intensive home
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive home treatment
Study: 33857800
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose group (n = 10) performed 4320 steps
Study: 33857800
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose group (n = 10) performed 144 steps
Study: 32792771
Drug: Intralesional injection
Normalized name: DEXAMETHASONE SODIUM PHOSPHATE 4 mg in 1 mL INTRALESIONAL INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional injection of triamcinolone acetonide (10 mg/mL)
Study: 32792771
Drug: Intralesional autologous
Normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional autologous platelet-rich plasma (PRP) injection
Study: 36658607
Drug: Spa therapy
Normalized name: Broda Acne Spa
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spa therapy alone
Study: 32791665
Drug: Sirolimus 2
Normalized name: sirolimus 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sirolimus 2 mg orally once daily for 16 weeks
Study: 35891255
Drug: Double dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double dose (DD) of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine
Study: 35891255
Drug: Normal dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal dose (ND) of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine
Study: 35891255
Drug: Double dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double dose (DD)
Study: 32289292
Drug: 0 medications
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0 medications
Study: 32289292
Drug: 1 medication
Normalized name: tolnaftate
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 medication
Study: 32289292
Drug: 2 medications
Normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 medications
Study: 32289292
Drug: 3 medications
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3 medications
Study: 33027799
Drug: High tertile
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High tertile of net ultrafiltration (NUF) rate (>1.75 mL/kg/h)
Study: 33027799
Drug: Middle tertile
Normalized name: wheat middlings extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Middle tertile of net ultrafiltration (NUF) rate (1.01-1.75 mL/kg/h)
Study: 33027799
Drug: Low tertile
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low tertile of net ultrafiltration (NUF) rate (<1.01 mL/kg/h)
Study: 35448970
Drug: Virtual reality-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual reality-based vision therapy
Study: 34598980
Drug: TENS (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: TENS (daily home-based for 5 weeks)
Study: 32589230
Drug: Apixaban (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apixaban (2.5 mg orally twice daily)
Study: 32589230
Drug: Enoxaparin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (40 mg subcutaneously daily)
Study: 36356410
Drug: EVE esc
Normalized name: Summer's Eve Medicated
Approvals — FDA: no, EMA: no, PMDA: no
Description: EVE esc (2.5 mg/day week 1; 5 mg/day week 2; 7.5 mg/day week 3; 10 mg/day weeks 4-24)
Study: 36356410
Drug: EVE 10mg
Normalized name: Summer's Eve Medicated
Approvals — FDA: no, EMA: no, PMDA: no
Description: EVE 10mg (10 mg/day for 24 weeks plus exemestane)
Study: 37721964
Drug: All treatment
Normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatment regimens
Study: 32564571
Drug: Clopidogrel 75
Normalized name: clopidogrel 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 75 mg qd
Study: 36035935
Drug: Original dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Original dose of neurohumoral blockades
Study: 36035935
Drug: Halved dose
Normalized name: VALVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Halved dose of neurohumoral blockades
Study: 36035935
Drug: Both doses
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both doses of neurohumoral blockades
Study: 36042633
Drug: Phellinus linteus
Normalized name: PHELLINUS LINTEUS WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phellinus linteus extract (1000 mg per day for 8 weeks)
Study: 36042633
Drug: Placebo (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1000 mg dextrin per day for 8 weeks)
Study: 34023318
Drug: Personalized-dose corticosteroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized-dose corticosteroid therapy for 5 days
Study: 34023318
Drug: Fixed-dose corticosteroid
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose corticosteroid therapy (40 mg of prednisolone) for 5 days
Study: 34023318
Drug: Personalized-dose corticosteroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized-dose corticosteroid therapy
Study: 34023318
Drug: Fixed-dose corticosteroid
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose corticosteroid therapy
Study: 34023318
Drug: Personalized-dose corticosteroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized-dose corticosteroid therapy (40 mg or less)
Study: 34023318
Drug: Personalized-dose corticosteroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized-dose corticosteroid therapy (more than 40 mg)
Study: 33032560
Drug: Absorbable skin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Absorbable skin suture with closure of the subcutaneous fascia (Group 4)
Study: 33032560
Drug: Non-absorbable skin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-absorbable skin suture with closure of the subcutaneous fascia (Group 3)
Study: 33032560
Drug: Absorbable skin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Absorbable skin suture without closure of the subcutaneous fascia (Group 2)
Study: 33032560
Drug: Non-absorbable skin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-absorbable skin suture without closure of the subcutaneous fascia (Group 1)
Study: 33890902
Drug: Silver sulfadiazine
Normalized name: Silver Sulfadiazine
DrugBank: Silver sulfadiazine (DB05245)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silver sulfadiazine cream 1%
Study: 616886766
Drug: Modified Sanxiang
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified Sanxiang Xiaopi decoction (80 mL through a stomach tube for 14 days)
Study: 33917503
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Lactoplantibacillus plantarum strains CECT7527, CECT7528, and CECT7529 plus 10 mg of monacolin K
Study: 32163723
Drug: Percentage time
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percentage time in glucose target 70-180 mg/dL
Study: 33632215
Drug: Digital information
Normalized name: INFORMATION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital information tool with VR-technology and standard care (oral and written information)
Study: 33632215
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care and information (oral and written)
Study: 34741564
Drug: Control (rescue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (rescue therapy)
Study: 32762725
Drug: Functional ability
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional ability on ADL (Activities of Daily Living)
Study: 32762725
Drug: Functional ability
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional ability on IADL (Instrumental Activities of Daily Living)
Study: 35032443
Drug: Daily bathing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily bathing with 2% chlorhexidine gluconate (CHG) detergent solution
Study: 35032443
Drug: Daily bathing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily bathing with pH neutral soap and water
Study: 33865308
Drug: Balance exercises
Normalized name: Rebalance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balance exercises during daily tooth brushing (twice daily for three minutes over eight weeks)
Study: 36096771
Drug: High molecular
Normalized name: dextran, high molecular weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: High molecular weight hyaluronic acid (HA) injections
Study: 36096771
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of PRP and HA injections (PRP+HA)
Study: 35109584
Drug: Multimodal personalized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal personalized lifestyle intervention (dietary and physical activity counseling and cognitive training) combined with dietary supplement epigallocatechin gallate (EGCG)
Study: 32873263
Drug: BPB (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: BPB (100 g)
Study: 32873263
Drug: PB (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: PB (100 g)
Study: 33813559
Drug: Omidenepag isopropyl
Normalized name: Omidenepag isopropyl
DrugBank: Omidenepag isopropyl (DB15071)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Omidenepag isopropyl 0.002% once daily (QD)
Study: 33813559
Drug: Omidenepag isopropyl
Normalized name: Omidenepag isopropyl
DrugBank: Omidenepag isopropyl (DB15071)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Omidenepag isopropyl 0.002% twice daily (BID)
Study: 32696102
Drug: Topical tobramycin
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Topical tobramycin 0.3%/dexamethasone 0.1% plus ozonized oil eye drops, four times daily for seven days
Study: 32696102
Drug: Topical tobramycin
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Topical tobramycin 0.3%/dexamethasone 0.1% eye drops, four times daily for seven days
Study: 32696102
Drug: Topical tobramycin
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Topical tobramycin 0.3%/dexamethasone 0.1% plus ozonized oil eye drops
Study: 32696102
Drug: Topical tobramycin
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Topical tobramycin 0.3%/dexamethasone 0.1% eye drops
Study: 34161053
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy followed by cytoreductive surgery/hyperthermic intraperitoneal chemotherapy and adjuvant chemotherapy
Study: 32916500
Drug: 17 G
Normalized name: lancets 17 gauge MISCELL EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17 G needle
Study: 32916500
Drug: 18 G
Normalized name: flotufolastat F 18 gallium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18 G needle
Study: 35915512
Drug: TAU+ (treatment‐as‐usual
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAU+ (treatment‐as‐usual plus fitness tracker)
Study: 38775255
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 1200 mg
Study: 32559794
Drug: Juice group
Normalized name: tamarind juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Juice group (200 mL of liquid enriched with carbohydrate and protein 4 hours presurgery)
Study: 32559794
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (200 mL of inert solution 4 hours presurgery)
Study: 34592862
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg oral thiamine for 12 weeks
Study: 34592862
Drug: Over-the-counter (OTC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Over-the-counter (OTC) oral thiamine after 6 months
Study: 33693586
Drug: Oral antipseudomonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antipseudomonal antibiotics
Study: 33693586
Drug: Intravenous antipseudomonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous antipseudomonal antibiotics
Study: 33693586
Drug: Inhaled antipseudomonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled antipseudomonal antibiotics
Study: 33849629
Drug: SARS-CoV-2 vaccine
Normalized name: SARS-CoV-2 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: SARS-CoV-2 vaccine (inactivated, Vero cell)
Study: 32703746
Drug: 5-dose MCV
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-dose MCV vials
Study: 32703746
Drug: 10-dose MCV
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-dose MCV vials
Study: 34596156
Drug: Pulsed magnetic
Normalized name: MAGNESIA
DrugBank: Magnesium oxide (DB01377)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pulsed magnetic therapy
Study: 34596156
Drug: Combined magnetic
Normalized name: MAGNESIA
DrugBank: Magnesium oxide (DB01377)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined magnetic therapy and exercise therapy
Study: 34596156
Drug: Routine medical
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine medical treatment (Control)
Study: 35917985
Drug: Triple antibiotic
Normalized name: Triple Antibiotic
DrugBank: Polymyxin B (DB00781)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triple antibiotic paste, Calcium Hydroxide, and Saline
Study: 32394653
Drug: Electroacupuncture (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture (EA) at Neiguan (PC 6) and Shuigou (GV 26) with disperse-dense wave, 2 Hz/100 Hz in frequency, 0.1-5 mA in intensity, treatment performed once a day for 14 consecutive days.
Study: 32394653
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group treated with awakening drugs and neurotrophic drugs.
Study: 32406162
Drug: Microneedling plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microneedling plus topical 4% tranexamic acid
Study: 32406162
Drug: Topical 4%
Normalized name: menthol topical 4% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 4% hydroquinone
Study: 35715486
Drug: Daily mother-infant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily mother-infant skin-to-skin contact (SSC) for one hour during the first five postnatal weeks
Study: 35715486
Drug: Daily mother-infant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily mother-infant skin-to-skin contact (SSC) (per-protocol analysis)
Study: 35715486
Drug: Daily mother-infant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily mother-infant skin-to-skin contact (SSC)
Study: 33751906
Drug: l-theanine (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-theanine (single dose)
Study: 33751906
Drug: l-theanine (regular
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-theanine (regular intake for 12 weeks)
Study: 35869143
Drug: Subsequent therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subsequent therapies
Study: 37495797
Drug: Drug-coated balloons
Normalized name: erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug-coated balloons (DCB)
Study: 34096661
Drug: Cranial microcurrent
Normalized name: geranial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranial microcurrent stimulation (CMS); intensity, 25 μA; frequency, 8 Hz; 20-minute daily treatment for 2 weeks.
Study: 34096661
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment (no current).
Study: 35698001
Drug: Alfentanil 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil 0.2 μg/kg/min
Study: 35698001
Drug: Alfentanil 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil 0.4 μg/kg/min
Study: 35698001
Drug: Alfentanil 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil 0.2 μg/kg/min vs Normal saline
Study: 36243712
Drug: Starch tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starch tablets (Control)
Study: 33370476
Drug: Digital grayscale
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital grayscale intra-oral scans
Study: 39587622
Drug: Saline (placebo)
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline (placebo) injection
Study: 33504040
Drug: Mirror Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirror Therapy Action Observation (MTAO)
Study: 39599964
Drug: Action Observation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Action Observation Therapy (AOT)
Study: 32881835
Drug: Resveratrol supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resveratrol supplementation (75 mg BID)
Study: 32742515
Drug: Haloperidol (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (0.5 cc, 5 mg)
Study: 32742515
Drug: Metoclopramide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (10 mg, given 30 minutes before surgery)
Study: 32742515
Drug: Dexmedetomidine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (25 μg)
Study: 32742515
Drug: Ginger (four
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginger (four capsules with a hint of lemon)
Study: 35683427
Drug: Convalescent plasma
Normalized name: Convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Convalescent plasma (600 mL divided into two doses administered on days 1 and 2)
Study: 35683427
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment alone (Control group)
Study: 32873093
Drug: Morning BTA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning BTA injections
Study: 32873093
Drug: Afternoon BTA
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Afternoon BTA injections
Study: 35028684
Drug: Conventional contrast
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional contrast material (CM) injection protocol based on body weight
Study: 35523495
Drug: Transdermal electrical
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal electrical stimulation (TdES) with skin electrodes
Study: 33580809
Drug: Preoperative pelvic
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative pelvic floor muscle training (PFMT) daily from inclusion to the day of surgery
Study: 35166373
Drug: Oral paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral paracetamol (0.6 ml.kg‐1, 24 mg.ml‐1 concentration)
Study: 35166373
Drug: Water alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water alone (3.6 ml.kg‐1)
Study: 36200545
Drug: Percutaneous treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous treatment (35.0% in 2020 vs. 25.9% in 2019; p < 0.0001)
Study: 35664492
Drug: Venlafaxine 150
Normalized name: venlafaxine 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine 150 mg daily
Study: 33261932
Drug: Esketamine nasal
Normalized name: esketamine Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esketamine nasal spray combined with a new oral antidepressant (AD)
Study: 33261932
Drug: Placebo combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo combined with a new oral antidepressant (AD)
Study: 32756846
Drug: Chemical weeding
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemical weeding treatments
Study: 33354815
Drug: 0.15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15 mg/kg intravenous subdissociative ketamine (low dose)
Study: 33354815
Drug: 0.30 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.30 mg/kg intravenous subdissociative ketamine (high dose)
Study: 37395841
Drug: Mindfulness-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-based therapy
Study: 36180944
Drug: Liver transplantation
Normalized name: LIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liver transplantation (LT) + best established treatment (BET)
Study: 36180944
Drug: Best established
Normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best established treatment (BET) only
Study: 34624138
Drug: Myo-inositol and
Normalized name: myo-inositol
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Myo-inositol and d-chiro-inositol combination (MI + DCI) 550 + 150 mg, twice a day for 6 months
Study: 34624138
Drug: Combined hormonal
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined hormonal contraceptive (CHC) (ethinyl estradiol 20 µg + drospirenone 3 mg), once a day for 6 months